Resistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment in hematologic malignancies. Even though main mechanisms of resistance are the same in different types of tumours there are specific signalling pathways involved in resistance in hematological malignancies and of course specific treatments In 11 chapters, Resistance in Hematologic Malignancies and Cancer describes the development of treatment resistance in hematological malignancies, the role of MiRNA in resistance, the role of the immune system in resistance prediction, as well as the latest knowledge from clinical research. It gives insight in the complex information about different mechanisms linkage in final loss of cell sensitivity to drug treatment, the orientation in metabolic pathways that could be involved in depressed leukemia cell resistance to drugs and gives information about causes of drug resistance in leukemia cells. By the multidisciplinary approach of the processing this book is a valuable resource for both health professionals, scientists and researchers, health practitioners, students, but will also enable members of the general professional public to orientate themselves in issues that are not directly in their area of expertise
1. Title of Book - p. ii 2. Cover image - p. ii 3. Title page - p. ii 4. Table of Contents - p. ii 5. Front Matter - p. i 6. Copyright - p. iii 7. Cover Image Insert - p. iii 8. Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy” - p. iii 9. About the Series Editor - p. iii 10. Aims and Scope of Volume - p. iii 11. Volume Editor Biography - p. xiii 12. Preface - p. xv 13. Contributors - p. xxi 14. Chapter 1. Drug classification for the treatment of hematologic malignancies - p. 1 15. Chapter 2. Reduce drug uptake in the development of resistance - p. 53 16. Chapter 3. The role of enhanced drug efflux in drug resistance - p. 77 17. Chapter 4. MicroRNAs and other noncoding RNA species in diagnostics, prognostics and therapy response of blood cancers - p. 123 18. Chapter 5. Switching between autophagy and apoptosis prosurvival and prodeath balance in leukemia cells - p. 139 19. Chapter 6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy - p. 165 20. Chapter 7. Altered cell cycle regulation in the development of resistance - p. 193 21. Chapter 8. Deregulation of drug metabolizing enzymes and transporters in cancer via altered aryl hydrocarbon receptor signaling - p. 220 22. Chapter 9. Immune system in resistance prediction - p. 237 23. Chapter 10. Mechanisms of resistance of antibody-drug conjugates—Obstacles to overcome - p. 257 24. Chapter 11. Resistance to chimeric antigen receptor T cells (CAR-T) - p. 275 25. Index - p. 293
Resistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment in hematologic malignancies. Even though main mechanisms of resistance are the same in different types of tumours there are specific signalling pathways involved in resistance in hematological malignancies and of course specific treatments In 11 chapters, Resistance in Hematologic Malignancies and Cancer describes the development of treatment resistance in hematological malignancies, the role of MiRNA in resistance, the role of the immune system in resistance prediction, as well as the latest knowledge from clinical research. It gives insight in the complex information about different mechanisms linkage in final loss of cell sensitivity to drug treatment, the orientation in metabolic pathways that could be involved in depressed leukemia cell resistance to drugs and gives information about causes of drug resistance in leukemia cells. By the multidisciplinary approach of the processing this book is a valuable resource for both health professionals, scientists and researchers, health practitioners, students, but will also enable members of the general professional public to orientate themselves in issues that are not directly in their area of expertise
1. Title of Book - p. ii 2. Cover image - p. ii 3. Title page - p. ii 4. Table of Contents - p. ii 5. Front Matter - p. i 6. Copyright - p. iii 7. Cover Image Insert - p. iii 8. Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy” - p. iii 9. About the Series Editor - p. iii 10. Aims and Scope of Volume - p. iii 11. Volume Editor Biography - p. xiii 12. Preface - p. xv 13. Contributors - p. xxi 14. Chapter 1. Drug classification for the treatment of hematologic malignancies - p. 1 15. Chapter 2. Reduce drug uptake in the development of resistance - p. 53 16. Chapter 3. The role of enhanced drug efflux in drug resistance - p. 77 17. Chapter 4. MicroRNAs and other noncoding RNA species in diagnostics, prognostics and therapy response of blood cancers - p. 123 18. Chapter 5. Switching between autophagy and apoptosis prosurvival and prodeath balance in leukemia cells - p. 139 19. Chapter 6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy - p. 165 20. Chapter 7. Altered cell cycle regulation in the development of resistance - p. 193 21. Chapter 8. Deregulation of drug metabolizing enzymes and transporters in cancer via altered aryl hydrocarbon receptor signaling - p. 220 22. Chapter 9. Immune system in resistance prediction - p. 237 23. Chapter 10. Mechanisms of resistance of antibody-drug conjugates—Obstacles to overcome - p. 257 24. Chapter 11. Resistance to chimeric antigen receptor T cells (CAR-T) - p. 275 25. Index - p. 293
